H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on CytoDyn Inc (CYDY) today and set a price target of $1.50. The company’s shares closed yesterday at $0.59.
According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -12.6% and a 25.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Bausch Health Companies Inc, and Aerpio Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CytoDyn Inc with a $1.50 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $0.84 and a one-year low of $0.40. Currently, CytoDyn Inc has an average volume of 223K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus infection. Its product pipeline includes PRO 140, CytoFeline, and Cytolin.
